6% Convertible Senior Notes due
June 2014
J.P. Morgan
Securities Inc.
Merrill Lynch, Pierce, Fenner & Smith Incorporated
As
Representatives of the
several Initial Purchasers listed
in Schedule 1 hereto
c/o J.P. Morgan
Securities Inc.
383 Madison Avenue
New York, New York 10179
Liz Claiborne, Inc., a Delaware corporation (the
“Company”), proposes to issue and sell to the several
initial purchasers listed in Schedule 1 hereto (the
“Initial Purchasers”), for whom you are acting as
representatives (the “Representatives”), $75,000,000
principal amount of its 6% Convertible Senior Notes due 2014 (the
“Underwritten Securities”) and, at the option of the
Initial Purchasers, up to an additional $15,000,000 principal
amount of its 6% Convertible Senior Notes due 2014 (the
“Option Securities”) if, and to the extent that, the
Initial Purchasers shall have determined to exercise the option to
purchase such 6% Convertible Senior Notes due 2014 granted to the
Initial Purchasers in Section 2 hereof. The Underwritten
Securities and the Option Securities are herein referred to as the
“Securities.” The Securities will be convertible into
shares (the “Underlying Securities”) of common stock of
the Company, par value $1.00 per share (the “Common
Stock”). The Securities will be issued pursuant to an
indenture to be dated as of June 24, 2009 (the
“Indenture”) between the Company and The Bank of New
York Mellon, as trustee (the “Trustee”). The Common
Stock will have attached thereto rights (the “Rights”)
to purchase one one-hundredth of a share of Series A Junior
Participating Preferred Stock, par value $0.01 per share, at a
purchase price of $150.00 per share, subject to adjustment (the
“Series A Preferred Stock”). The Rights are to be
issued pursuant to a rights agreement, dated as of December 4,
1998 and amended on November 11, 2001 and December 19, 2009
between the Company and The Bank of New York Mellon, as Rights
Agent (as amended, the “Rights Agreement”).
The Company hereby confirms its agreement with
the several Initial Purchasers concerning the purchase and sale of
the Securities, as follows:
1. The Securities will be sold to the
Initial Purchasers without being registered under the Securities
Act of 1933, as amended (the “Securities Act”), in
reliance upon an exemption therefrom. The Company has prepared a
preliminary offering memorandum dated June 17, 2009 (the
“Preliminary Offering Memorandum”) and will prepare an
offering memorandum dated the date hereof (the “Offering
Memorandum”) setting forth information concerning the Company
and the Securities. Copies of the Preliminary Offering Memorandum
have been, and copies of the Offering Memorandum will be, delivered
by the Company to the Initial Purchasers pursuant to the terms of
this Agreement. The Company hereby confirms that it has authorized
the use of the Preliminary Offering Memorandum, the other Time of
Sale Information (as defined below) and the Offering Memorandum in
connection with the offering and resale of the Securities by the
Initial Purchasers in the manner contemplated by this Agreement.
References herein to the Preliminary Offering Memorandum, the Time
of Sale Information and the Offering Memorandum shall be deemed to
refer to and include any document incorporated by reference
therein.
At or prior to the time when sales of the
Underwritten Securities were first made (the “Time of
Sale”), the Company had prepared the following information
(collectively, the “Time of Sale Information”): the
Preliminary Offering Memorandum, as supplemented and amended by the
written communications listed on Annex C hereto.
In connection with the transactions described in
this Agreement, the Company will enter into an amendment to the
Company’s amended and restated credit agreement dated as of
January 12, 2009 and amended as of May 12, 2009 (the
“Credit Agreement”), dated June 15, 2009 among
itself, the guarantors named therein and the lenders named therein
(the “Amendment”).
2. Purchase and Resale of the
Securities by the Initial Purchasers . (a) The Company
agrees to issue and sell the Underwritten Securities to the several
Initial Purchasers as provided in this Agreement, and each Initial
Purchaser, on the basis of the representations, warranties and
agreements set forth herein and subject to the conditions set forth
herein, agrees, severally and not jointly, to purchase from the
Company the respective principal amount of Underwritten Securities
set forth opposite such Initial Purchaser’s name in
Schedule 1 hereto at a price equal to 97% of the principal
amount thereof (the “Purchase Price”) plus accrued
interest, if any, from June 24, 2009 to the Closing Date (as
defined below).
In addition, the Company agrees to issue and
sell the Option Securities to the several Initial Purchasers as
provided in this Agreement, and the Initial Purchasers, on the
basis of the representations, warranties and agreements set forth
herein and subject to the conditions set forth herein, shall have
the option to purchase, severally and not jointly, from the Company
the Option Securities at the Purchase Price plus accrued interest,
if any, from the Closing Date to the date of payment and
delivery.
If any Option Securities are to be purchased,
the amount of Option Securities to be purchased by each Initial
Purchaser shall be the amount of Option Securities which bears the
same ratio to the aggregate amount of Option Securities being
purchased as the amount of Underwritten Securities set forth
opposite the name of such Initial Purchaser in Schedule 1
hereto (or such amount increased as set forth in Section 10
hereof) bears to the aggregate amount of Underwritten Securities
being purchased from the Company by the several Initial Purchasers,
subject, however, to such adjustments to eliminate Securities in
denominations other than $1,000.00 as the Representatives in its
sole discretion shall make.
2
The Initial Purchasers may exercise the option
to purchase the Option Securities at any time in whole, or from
time to time in part, on or before the thirteenth day following the
Closing Date, by written notice from the Representatives to the
Company. Such notice shall set forth the aggregate amount of Option
Securities as to which the option is being exercised and the date
and time when the Option Securities are to be delivered and paid
for which may be the same date and time as the Closing Date but
shall not be earlier than the Closing Date nor later than the tenth
full business day (as defined below) after the date of such notice
(unless such time and date are postponed in accordance with the
provisions of Section 10 hereof). Any such notice shall be
given at least two business days prior to the date and time of
delivery specified therein.
(b) The Company understands that the
Initial Purchasers intend to offer the Securities for resale on the
terms set forth in the Time of Sale Information. Each Initial
Purchaser, severally and not jointly, represents, warrants and
agrees that:
(i) it is a qualified institutional buyer
(a “QIB”) as defined in Rule 144A under the
Securities Act (“Rule 144A”) and an accredited
investor as defined in Rule 501(a) under the Securities
Act;
(ii) it has not solicited offers for, or
offered or sold, and will not solicit offers for, or offer or sell,
the Securities by means of any form of general solicitation or
general advertising within the meaning of Rule 502(c) of
Regulation D under the Securities Act
(“Regulation D”) or in any manner involving a
public offering within the meaning of Section 4(2) of the
Securities Act; and
(iii) it has not solicited offers for, or
offered or sold, and will not solicit offers for, or offer or sell,
the Securities as part of their initial offering except to persons
whom it reasonably believes to be QIBs in transactions pursuant to
Rule 144A and in connection with each such sale, it has taken
or will take reasonable steps to ensure that the purchaser of the
Securities is aware that such sale is being made in reliance on
Rule 144A.
(c) Each Initial Purchaser acknowledges and
agrees that the Company and, for purposes of the opinions to be
delivered to the Initial Purchasers pursuant to Sections 6(f),
6(g) and 6(h), counsel for the Company, the Company’s General
Counsel and counsel for the Initial Purchasers, respectively, may
rely upon the accuracy of the representations and warranties of the
Initial Purchasers, and compliance by the Initial Purchasers with
their agreements, contained in paragraph (b) above, and each
Initial Purchaser hereby consents to such reliance.
(d) The Company acknowledges and agrees
that the Initial Purchasers may offer and sell Securities to or
through any affiliate of an Initial Purchaser and that any such
affiliate may offer and sell Securities purchased by it to or
through any Initial Purchaser.
3
(e) Payment for the Securities shall be
made by wire transfer in immediately available funds to the account
specified by the Company to the Representatives in the case of the
Underwritten Securities, at the offices of Davis Polk &
Wardwell at 10:00 A.M. New York City time on June 24,
2009, or at such other time or place on the same or such other
date, not later than the fifth business day thereafter, as the
Representatives and the Company may agree upon in writing or, in
the case of the Option Securities, on the date and at the time and
place specified by the Representatives in the written notice of the
Initial Purchasers’ election to purchase such Option
Securities. The time and date of such payment for the Underwritten
Securities is referred to herein as the “Closing Date”
and the time and date for such payment for the Option Securities,
if other than the Closing Date, is herein referred to as the
“Additional Closing Date”.
Payment for the Securities to be purchased on
the Closing Date or the Additional Closing Date, as the case may
be, shall be made against delivery to the nominee of DTC, for the
respective accounts of the several Initial Purchasers of the
Securities to be purchased on such date of one or more global notes
representing the Securities (collectively, the “Global
Note”), with any transfer taxes payable in connection with
the sale of such Securities duly paid by the Company. The Global
Note will be made available for inspection by the Representatives
at the office of J.P. Morgan Securities Inc. set forth above not
later than 1:00 P.M., New York City time, on the business day prior
to the Closing Date or the Additional Closing Date, as the case may
be.
(f) The Company acknowledges and agrees
that the Initial Purchasers are acting solely in the capacity of an
arm’s length contractual counterparty to the Company with
respect to the offering of Securities contemplated hereby
(including in connection with determining the terms of the
offering) and not as a financial advisor or a fiduciary to, or an
agent of, the Company or any other person. Additionally, neither
the Representatives nor any other Initial Purchaser is advising the
Company or any other person as to any legal, tax, investment,
accounting or regulatory matters in any jurisdiction. The Company
shall consult with its own advisors concerning such matters and
shall be responsible for making its own independent investigation
and appraisal of the transactions contemplated hereby, and the
Initial Purchasers shall have no responsibility or liability to the
Company with respect thereto. Any review by the Initial Purchasers
of the Company, the transactions contemplated hereby or other
matters relating to such transactions will be performed solely for
the benefit of the Initial Purchasers and shall not be on behalf of
the Company.
3. Representations and Warranties of
the Company . The Company represents and warrants to each
Initial Purchaser that:
(a) Preliminary Offering
Memorandum. The Preliminary Offering Memorandum, as of its
date, did not contain any untrue statement of a material fact or
omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which
they were made, not misleading; provided that the Company
makes no representation and warranty with respect to any statements
or omissions made in reliance upon and in conformity with
information relating to any Initial Purchaser furnished to the
Company in writing by such Initial Purchaser through the
Representatives expressly for use in any Preliminary Offering
Memorandum, it being understood and agreed that the only such
information furnished by any Initial Purchaser consists of the
information described as such in Section 7(b) hereof.
4
(b) Time of Sale Information . The
Time of Sale Information, at the Time of Sale, did not, and at the
Closing Date and as of the Additional Closing Date, as the case may
be, will not, contain any untrue statement of a material fact or
omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which
they were made, not misleading; provided that the Company
makes no representation and warranty with respect to any statements
or omissions made in reliance upon and in conformity with
information relating to any Initial Purchaser furnished to the
Company in writing by such Initial Purchaser through the
Representatives expressly for use in such Time of Sale Information,
it being understood and agreed that the only such information
furnished by any Initial Purchaser consists of the information
described as such in Section 7(b) hereof.
(c) Additional Written
Communications. Other than the Preliminary Offering Memorandum
and the Offering Memorandum, the Company (including its agents and
representatives, other than the Initial Purchasers in their
capacity as such) has not made, used, prepared, authorized,
approved or referred to and will not prepare, make, use, authorize,
approve or refer to any “written communication” (as
defined in Rule 405 under the Securities Act) that constitutes
an offer to sell or solicitation of an offer to buy the Securities
(each such communication by the Company or its agents and
representatives (other than a communication referred to in clauses
(i), (ii) and (iii) below) an “Issuer Written
Communication”) other than (i) the Preliminary Offering
Memorandum, (ii) the Offering Memorandum, (iii) the documents
listed on Annex C hereto, including a term sheet substantially in
the form of Annex D hereto, which constitute part of the Time of
Sale Information, and (iv) each electronic road show and any
other written communications approved in writing in advance by the
Representatives. Each such Issuer Written Communication, when taken
together with the Time of Sale Information, did not, and at the
Closing Date and as of the Additional Closing Date, as the case may
be, will not, contain any untrue statement of a material fact or
omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which
they were made, not misleading; provided that the Company
makes no representation and warranty with respect to any statements
or omissions made in each such Issuer Written Communication in
reliance upon and in conformity with information relating to any
Initial Purchaser furnished to the Company in writing by such
Initial Purchaser through the Representatives expressly for use in
such Issuer Written Communication, it being understood and agreed
that the only such information furnished by any Initial Purchaser
consists of the information described as such in Section 7(b)
hereof. Each such Issuer Written Communication, as of its issue
date and at all subsequent times through the completion of the
offer and sale of the Securities or until any earlier date that the
Company notified or notifies the Representatives as described in
Section 4(e), did not, does not and will not include any
information that conflicted, conflicts or will conflict with the
information contained in the Time of Sale Information or the
Offering Memorandum, including any document incorporated by
reference therein.
(d) Offering Memorandum. As of the
date of the Offering Memorandum and as of the Closing Date and as
of the Additional Closing Date, as the case may be, the Offering
Memorandum does not and will not contain any untrue statement of a
material fact or omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances
under which they were made, not misleading; provided that
the Company makes no representation and warranty with respect to
any statements or omissions made in reliance upon and in conformity
with information relating to any Initial Purchaser furnished to the
Company in writing by such Initial Purchaser through the
Representatives expressly for use in the Offering Memorandum, it
being understood and agreed that the only such information
furnished by any Initial Purchaser consists of the information
described as such in Section 7(b) hereof.
5
(e) Incorporated Documents. Each of
the documents incorporated by reference in the Offering Memorandum
or the Time of Sale Information, when filed with the Commission
complied or will comply as to form, as the case may be, in all
material respects to the requirements of the Securities Exchange
Act of 1934, as amended, and the rules and regulations of the
Commission thereunder (collectively, the “Exchange
Act”).
(f) Financial Statements. The
financial statements and the related notes thereto of the Company
and its consolidated subsidiaries included or incorporated by
reference the Time of Sale Information and the Offering Memorandum
present fairly in all material respects the financial position of
the Company and its consolidated subsidiaries as of the dates
indicated and the results of their operations and the changes in
their cash flows for the periods specified; such financial
statements have been prepared in conformity with U.S. generally
accepted accounting principles applied on a consistent basis
throughout the periods covered thereby; and the other financial
information included or incorporated by reference in the Time of
Sale Information and the Offering Memorandum has been derived from
the accounting records of the Company and its consolidated
subsidiaries and presents fairly in all material respects the
information shown thereby.
(g) No Material Adverse Change.
Since the date of the most recent financial statements of the
Company included or incorporated by reference in the Time of Sale
Information and the Offering Memorandum, (i) there has not
been any change in the capital stock, long-term debt, notes payable
or current portion of long-term debt of the Company or any of its
subsidiaries, or any dividend or distribution of any kind declared,
set aside for payment, paid or made by the Company on any class of
capital stock, or any material adverse change, or any development
that is reasonably likely to result in a material adverse change,
in or affecting the business, properties, management, financial
position, stockholders’ equity, results of operations or
prospects of the Company and its subsidiaries taken as a whole;
(ii) neither the Company nor any of its subsidiaries has
entered into any transaction or agreement that is material to the
Company and its subsidiaries taken as a whole or incurred any
liability or obligation, direct or contingent, that is material to
the Company and its subsidiaries taken as a whole; and
(iii) neither the Company nor any of its subsidiaries has
sustained any material loss or interference with its business from
fire, explosion, flood or other calamity, whether or not covered by
insurance, or from any labor disturbance or dispute or any action,
order or decree of any court or arbitrator or governmental or
regulatory authority, except, in each case, as otherwise disclosed
in or expressly contemplated by the Time of Sale Information and
the Offering Memorandum.
6
(h) Organization and Good Standing.
The Company and each of its “significant subsidiaries”
(as defined in Rule 1-02 of Regulation S-X) have been
duly organized and are validly existing and in good standing under
the laws of their respective jurisdictions of organization, are
duly qualified to do business and are in good standing in each
jurisdiction in which their respective ownership or lease of
property or the conduct of their respective businesses requires
such qualification, and have all power and authority necessary to
own or hold their respective properties and to conduct the
businesses in which they are engaged, except where the failure to
be so qualified or in good standing or have such power or authority
would not, individually or in the aggregate, be reasonably expected
to have a material adverse effect on the business, properties,
management, financial position, stockholders’ equity, results
of operations or prospects of the Company and its subsidiaries
taken as a whole or on the performance by the Company of its
obligations under the Transaction Documents (as defined below) (a
“Material Adverse Effect”). The jurisdictions in which
the Company is required to be qualified to do business, except for
those jurisdictions where the failure to be so qualified would not
have a Material Adverse Effect, are listed on Schedule 2. The
Company does not own or control, directly or indirectly, any
corporation, association or other entity other than the
subsidiaries listed in Schedule 3 to this
Agreement.
(i) Capitalization. The Company has
an authorized equity capitalization as set forth in the Time of
Sale Information and the Offering Memorandum under the heading
“Capitalization,” all the outstanding shares of capital
stock of the Company have been duly and validly authorized and
issued and are fully paid and non-assessable and are not subject to
any pre-emptive or similar rights; except as described in or
expressly contemplated by the Time of Sale Information and the
Offering Memorandum, there are no outstanding rights (including,
without limitation, pre-emptive rights), warrants or options to
acquire, or instruments convertible into or exchangeable for, any
shares of capital stock or other equity interest in the Company or
any of its subsidiaries, or any contract, commitment, agreement,
understanding or arrangement of any kind relating to the issuance
of any capital stock of the Company or any such subsidiary, any
such convertible or exchangeable securities or any such rights,
warrants or options; the capital stock of the Company conforms in
all material respects to the description thereof contained in the
Time of Sale Information and the Offering Memorandum; and all the
outstanding shares of capital stock or other equity interests of
each subsidiary owned, directly or indirectly, by the Company have
been duly and validly authorized and issued, are fully paid and
non-assessable (except, in the case of any foreign subsidiary, for
directors’ qualifying shares and except as otherwise
described in or expressly contemplated by the Time of Sale
Information and the Offering Memorandum) and are owned directly or
indirectly by the Company, free and clear of any lien, charge,
encumbrance, security interest, restriction on voting or transfer
or any other claim of any third party; except as described in the
Time of Sale Information and except for any such liens, charges,
encumbrances and security interests incurred pursuant to the Credit
Agreement.
(j) Due Authorization. The Company
has full right, power and authority to execute and deliver this
Agreement, the Indenture, the Securities and the Amendment
(collectively, the “Transaction Documents”) and to
perform its obligations hereunder and thereunder; and all action
required to be taken for the due and proper authorization,
execution and delivery by it of each of the Transaction Documents
and the consummation by it of the transactions contemplated thereby
or by the Time of Sale Information and the Offering Memorandum has
been duly and validly taken.
7
(k) Indenture . The Indenture has
been duly authorized by the Company and, when duly executed and
delivered in accordance with its terms by each of the parties
thereto, will constitute a valid and legally binding agreement of
the Company, enforceable against the Company in accordance with its
terms, except as enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, fraudulent conveyance or
transfer, moratorium or similar laws affecting creditors’
rights generally or by general principles of equity (regardless of
whether enforceability is considered in a proceeding in equity or
at law) (collectively, the “Enforceability
Exceptions”); and on the Closing Date, the Indenture will
conform in all material respects to the requirements of the Trust
Indenture Act of 1939, as amended (the “Trust Indenture
Act”), and the rules and regulations of the Commission
applicable to an indenture that is qualified thereunder.
(l) Purchase Agreement. This
Agreement has been duly authorized, executed and delivered by the
Company.
(m) S ecurities. The Securities have
been duly authorized by the Company and, when duly executed,
authenticated, issued and delivered as provided in the Indenture
and paid for as provided herein, will constitute valid and legally
binding obligations of the Company, enforceable against the Company
in accordance with their terms, subject to the Enforceability
Exceptions, and will be entitled to the benefits of the
Indenture.
(n) Underlying Securities . Upon
issuance and delivery of the Securities in accordance with this
Agreement and the Indenture, the Securities will be convertible at
the option of the holder thereof into shares of the Underlying
Securities in accordance with the terms of the Securities; the
Underlying Securities reserved for issuance upon conversion of the
Securities have been duly authorized and reserved and, when issued
upon conversion of the Securities in accordance with the terms of
the Securities and the Indenture, delivered as provided in the
Indenture and paid for as provided herein, will be validly issued,
fully paid and non assessable, and the issuance of the Underlying
Securities will not be subject to any preemptive or similar rights;
the Rights Agreement has been duly authorized, executed and
delivered by the Company and constitutes a valid and legally
binding agreement of the Company enforceable against the Company in
accordance with its terms, subject to the Enforceability
Exceptions; and the Rights have been duly authorized by the Company
and, when issued upon issuance of the Underlying Securities, will
be validly issued, and the Series A Preferred Stock underlying such
Rights has been duly authorized by the Company and validly reserved
for issuance upon the exercise in accordance with the terms of the
Rights Agreement, will be validly issued, fully paid and
non-assessable.
(o) Other Transaction Documents.
The Amendment has been duly authorized, executed and delivered by
the Company and, assuming the due execution and delivery thereof by
the other parties thereto, constitutes a valid and legally binding
agreement of the Company and enforceable against the Company in
accordance with its terms, subject to the Enforceability
Exceptions.
(p) Descriptions of the Transaction
Documents. Each Transaction Document conforms in all material
respects to the description thereof contained in the Time of Sale
Information and the Offering Memorandum.
8
(q) No Violation or Default.
Neither the Company nor any of its subsidiaries is (i) in
violation of its charter or by-laws or similar organizational
documents; (ii) in default, and no event has occurred that,
with notice or lapse of time or both, would constitute such a
default, in the due performance or observance of any term, covenant
or condition contained in any indenture, mortgage, deed of trust,
loan agreement or other agreement or instrument to which the
Company or any of its subsidiaries is a party or by which the
Company or any of its subsidiaries is bound or to which any of the
property or assets of the Company or any of its subsidiaries is
subject; or (iii) in violation of any law or statute or any
judgment, order, rule or regulation of any court or arbitrator or
governmental or regulatory authority, except, in the case of
clauses (ii) and (iii) above, for any such default or
violation that would not, individually or in the aggregate, be
reasonably expected to have a Material Adverse Effect or that is
disclosed in or is expressly contemplated by the Time of Sale
Information and the Offering Memorandum.
(r) No Conflicts. Assuming the
accuracy of, and the compliance with, the representations,
warranties and agreements set forth in this Agreement, the
execution, delivery and performance by the Company of each of the
Transaction Documents, the issuance and sale of the Securities
(including the issuance of the Underlying Securities upon
conversion thereof) and the consummation of the transactions
contemplated by the Transaction Documents or the Time of Sale
Information and the Offering Memorandum will not (i) conflict
with or result in a breach or violation of any of the terms or
provisions of, or constitute a default under, or result in the
creation or imposition of any lien, charge or encumbrance upon any
property or assets of the Company or any of its subsidiaries
pursuant to, any indenture, mortgage, deed of trust, loan agreement
or other agreement or instrument to which the Company or any of its
subsidiaries is a party or by which the Company or any of its
subsidiaries is bound or to which any of the property or assets of
the Company or any of its subsidiaries is subject (except as
otherwise described in the Time of Sale Information and the
Offering Memorandum), (ii) result in any violation of the
provisions of the charter or by-laws or similar organizational
documents of the Company or any of its subsidiaries or
(iii) result in the violation of any law or statute or any
judgment, order, rule or regulation of any court or arbitrator or
governmental or regulatory authority, except where such default or
violation (in the case of (i) or (iii)) would not,
individually or in the aggregate, be reasonably expected to have a
Material Adverse Effect.
(s) No Consents Required. Except as
disclosed in or expressly contemplated by the Time of Sale
Information and the Offering Memorandum, and assuming the accuracy
of, and the compliance with, the representations, warranties and
agreements set forth in this Agreement, no consent, approval,
authorization, order, registration or qualification of or with any
court or arbitrator or governmental or regulatory authority is
required for the execution, delivery and performance by the Company
of each of the Transaction Documents, the issuance and sale of the
Securities (including the issuance of the Underlying Securities
upon conversion thereof) and the consummation of the transactions
contemplated by the Transaction Documents or the Time of Sale
Information and the Offering Memorandum, except for such consents,
approvals, authorizations, orders and registrations or
qualifications as may be required under applicable state securities
or blue sky laws in connection with the purchase and resale of the
Securities by the Initial Purchasers.
9
(t) Legal Proceedings. Except as
described in or expressly contemplated by the Time of Sale
Information and the Offering Memorandum, there are no legal,
governmental or regulatory investigations, actions, suits or
proceedings pending to which the Company or any of its subsidiaries
is or may be a party or to which any property of the Company or any
of its subsidiaries is or may be the subject that, individually or
in the aggregate, would reasonably be expected to have a Material
Adverse Effect; no such investigations, actions, suits or
proceedings are threatened or, to the knowledge of the Company,
contemplated by any governmental or regulatory authority or
threatened by others.
(u) Independent Accountants.
Deloitte & Touche, LLP, who have certified certain financial
statements of the Company and its subsidiaries, are an independent
registered public accounting firm with respect to the Company and
its subsidiaries within the applicable rules and regulations
adopted by the Commission and the Public Company Accounting
Oversight Board (United States) and as required by the Securities
Act.
(v) Title to Real and Personal
Property. The Company and its subsidiaries have good and valid
title in fee simple to, or have valid rights to lease or otherwise
use, all items of real and personal property that are material to
the respective businesses of the Company and its subsidiaries, in
each case free and clear of all liens, encumbrances, claims and
defects and imperfections of title except those that (i) do
not materially interfere with the use made and proposed to be made
of such property by the Company and its subsidiaries or
(ii) would not reasonably be expected, individually or in the
aggregate, to have a Material Adverse Effect.
(w) Title to Intellectual Property.
Except as disclosed in or expressly contemplated by the Time of
Sale Information and the Offering Memorandum, (i) the Company
and its subsidiaries own or possess adequate rights to use all
material patents, patent applications, trademarks, service marks,
trade names, trademark registrations, service mark registrations,
copyrights, licenses and know-how (including trade secrets and
other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures) necessary for the conduct of
their respective businesses; and (ii) the conduct of their
respective businesses will not conflict in any material respect
with any such rights of others, and the Company and its
subsidiaries have not received any notice of any claim of
infringement of or conflict with any such rights of others, except,
in each case of (i) and (ii), as would not, individually or in
the aggregate, be reasonably expected to have a Material Adverse
Effect.
(x) No Undisclosed Relationships.
No relationship, direct or indirect, exists between or among the
Company or any of its subsidiaries, on the one hand, and the
directors, officers, stockholders, customers or suppliers of the
Company or any of its subsidiaries, on the other, that is required
by Item 404 of Regulation S-K of the Securities Act to be
described in a registration statement to be filed with the
Commission and that is not so described in the Time of Sale
Information and the Offering Memorandum.
(y) Investment Company Act. The
Company is not and, after giving effect to the offering and sale of
the Securities and the application of the proceeds thereof as
described in the Time of Sale Information and the Offering
Memorandum, will not be required to register as an
“investment company” or an entity
“controlled” by an “investment company”
within the meaning of the Investment Company Act of 1940, as
amended, and the rules and regulations of the Commission thereunder
(collectively, the “Investment Company
Act”).
10
(z) Taxes. The Company and its
subsidiaries have paid all federal, state, local and foreign taxes
and filed all tax returns required to be paid or filed through the
date hereof, except where the failure to so pay or so file would
not, individually or in the aggregate, be reasonably expected to
have a Material Adverse Effect; and except as otherwise disclosed
in or expressly contemplated by the Time of Sale Information and
the Offering Memorandum or as would not, individually or in the
aggregate, be reasonably expected to have a Material Adverse
Effect, there is no tax deficiency that has been, or could
reasonably be expected to be, asserted against the Company or any
of its subsidiaries or any of their respective properties or
assets.
(aa) Licenses and Permits. The
Company and its subsidiaries possess all licenses, certificates,
permits and other authorizations issued by, and have made all
declarations and filings with, the appropriate federal, state,
local or foreign governmental or regulatory authorities that are
necessary for the ownership or lease of their respective properties
or the conduct of their respective businesses as described in the
Time of Sale Information and the Offering Memorandum, except where
the failure to possess or make the same would not, individually or
in the aggregate, have a Material Adverse Effect; and except as
described in or expressly contemplated by the Time of Sale
Information and the Offering Memorandum, neither the Company nor
any of its subsidiaries has received notice of any revocation or
modification of any such license, certificate, permit or
authorization or has any reason to believe that any such license,
certificate, permit or authorization will not be renewed in the
ordinary course, except as would not, individually or in the
aggregate, be reasonably expected to have a Material Adverse
Effect.
(bb) No Labor Disputes. Except as
disclosed in or expressly contemplated by the Time of Sale
Information and the Offering Memorandum, no labor disturbance by or
dispute with employees of the Company or any of its subsidiaries
exists or, to the best knowledge of the Company, is contemplated or
threatened and the Company is not aware of any existing or imminent
labor disturbance by, or dispute with, the employees of any of its
or its subsidiaries’ principal suppliers, contractors or
customers, except as would not be reasonably expected to have a
Material Adverse Effect.
(cc) Compliance with Environmental
Laws. (i) The Company and its subsidiaries (x) are,
and at all prior times were, in compliance with any and all
applicable federal, state, local and foreign laws, rules,
regulations, requirements, decisions and orders relating to the
protection of human health or safety, the environment, natural
resources, hazardous or toxic substances or wastes, pollutants or
contaminants (collectively, “Environmental Laws”),
(y) have received and are in compliance with all permits,
licenses, certificates or other authorizations or approvals
required of them under applicable Environmental Laws to conduct
their respective businesses, and (z) have not received notice
of any actual or potential liability under or relating to any
Environmental Laws, including for the investigation or remediation
of any disposal or release of hazardous or toxic substances or
wastes, pollutants or contaminants, and have no knowledge of any
event or condition that would reasonably be expected to result in
any such notice, and (ii) there are no costs or liabilities
associated with Environmental Laws of or relating to the Company or
its subsidiaries; except in the case of each of (i) and
(ii) above, for any such failure to comply, or failure to
receive required permits, licenses or approvals, or cost or
liability, as would not, individually or in the aggregate, be
reasonably expected to have a Material Adverse Effect; and
(iii) except as described in or expressly contemplated by each
of the Time of Sale Information and the Offering Memorandum,
(x) there are no proceedings that are pending, or that are
known to be contemplated, against the Company or any of its
subsidiaries under any Environmental Laws in which a governmental
entity is also a party, other than such proceedings regarding which
it is reasonably believed no monetary sanctions of $100,000 or more
will be imposed, (y) the Company and its subsidiaries are not
aware of any issues regarding compliance with Environmental Laws,
or liabilities or other obligations under Environmental Laws or
concerning hazardous or toxic substances or wastes, pollutants or
contaminants, that would reasonably be expected to have a Material
Adverse Effect, and (z) none of the Company and its
subsidiaries anticipates material capital expenditures relating to
any Environmental Laws.
11
(dd) Hazardous Substances . Except
as disclosed in or expressly contemplated by the Time of Sale
Information and the Offering Memorandum, there has been no storage,
generation, transportation, handling, treatment, disposal,
discharge, emission, or other release of any kind of toxic wastes
or hazardous substances, including, but not limited to, any
naturally occurring radioactive materials, brine, drilling mud,
crude oil, natural gas liquids and other petroleum materials, by,
due to or caused by the Company or any of its subsidiaries (or, to
the best of the Company’s knowledge, any other entity
(including any predecessor) for whose acts or omissions the Company
or any of its subsidiaries is or could reasonably be expected to be
liable) upon any of the property now or previously owned or leased
by the Company or any of its subsidiaries, or upon any other
property, in violation of any Environmental Laws or in a manner or
to a location that could reasonably be expected to give rise to any
liability under the Environmental Laws, except for any violation or
liability which would not, individually or in the aggregate, be
reasonably expected to have a Material Adverse Effect.
(ee) Compliance with ERISA. Except
as disclosed in or expressly contemplated by the Time of Sale
Information and the Offering Memorandum, (i) each employee
benefit plan, within the meaning of Section 3(3) of the
Employee Retirement Income Security Act of 1974, as amended
(“ERISA”), for which the Company or any member of its
“Controlled Group” (defined as any organization which
is a member of a controlled group of corporations within the
meaning of Section 414 of the Internal Revenue Code of 1986,
as amended (the “Code”)) would have any liability
(each, a “Plan”) has been maintained in compliance with
its terms and the requirements of any applicable statutes, orders,
rules and regulations, including but not limited to ERISA and the
Code; (ii) no prohibited transaction, within the meaning of
Section 406 of ERISA or Section 4975 of the Code, has occurred
with respect to any Plan excluding transactions effected pursuant
to a statutory or administrative exemption; (iii) for each
Plan that is subject to the funding rules of Section 412 of
the Code or Section 302 of ERISA, no failure to satisfy the
minimum funding standards of Section 412 of the Code or
Section 302 of ERISA, has occurred or is reasonably expected
to occur; (iv) the fair market value of the assets of each
Plan exceeds the present value of all benefits accrued under such
Plan (determined based on those assumptions used to fund such
Plan); (v) no “reportable event” (within the
meaning of Section 4043(c) of ERISA) has occurred or is reasonably
expected to occur; and (vi) neither the Company nor any member
of the Controlled Group has incurred, nor reasonably expects to
incur, any liability under Title IV of ERISA (other than
contributions to the Plan or premiums to the PBGC, in the ordinary
course and without default) in respect of a Plan (including a
“multiemployer plan”, within the meaning of
Section 4001(a)(3) of ERISA), except as would not,
individually or in the aggregate, be reasonably expected to have a
Material Adverse Effect.
12
(ff) Disclosure Controls . The
Company and its subsidiaries maintain an effective system of
“disclosure controls and procedures” (as defined in
Rule 13a-15(e) of the Exchange Act) that is designed to ensure
that information required to be disclosed by the Company in reports
that it files or submits under the Exchange Act is recorded,
processed, summarized and reported within the time periods
specified in the Commission’s rules and forms, including
controls and procedures designed to ensure that such information
required to be disclosed in such reports is accumulated and
communicated to the Company’s management as appropriate to
allow timely decisions regarding required disclosure. The Company
and its subsidiaries have carried out evaluations of the
effectiveness of their disclosure controls and procedures as
required by Rule 13a-15 of the Exchange Act.
(gg) Accounting Controls. The
Company and its subsidiaries maintain systems of “internal
control over financial reporting” (as defined in
Rule 13a-15(f) of the Exchange Act) that comply with the
requirements of the Exchange Act and have been designed by, or
under the supervision of, their respective principal executive and
principal financial officers, or persons performing similar
functions, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles, including, but not limited to
policies and procedures that (i) pertain to the maintenance of
records that in reasonable detail accurately and fairly reflect the
transactions and dispositions of the assets of the Company,
(ii) provide reasonable assurance that transactions are
recorded as necessary to permit preparation of financial statements
in accordance with generally accepted accounting principles, and
that receipts and expenditures of the Company are being made only
in accordance with authorizations of management and directors of
the Company and (iii) provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use or
disposition of the Company’s assets that could have a
material effect on the financial statements. Except as disclosed in
the Time of Sale Information and the Offering Memorandum, there are
no “material weaknesses” (as defined in
Rule 1-02(a)(4) of Regulation S-X) in the Company’s
internal control over financial reporting. The Company’s
auditors and the Audit Committee of the Board of Directors of the
Company have been advised of: (i) all “significant
deficiencies” and “material weaknesses” (as
defined in Rule 1-02(a)(4) of Regulation S-X) in internal
control over financial reporting; and (ii) any fraud, whether
or not material, that involves management or other employees who
have a significant role in the Company’s internal control
over financial reporting.
(hh) Insurance. The Company and its
subsidiaries have insurance covering their respective properties,
operations, personnel and businesses, including business
interruption insurance, which insurance is in amounts and insures
against such losses and risks as are adequate to protect the
Company and its subsidiaries and their respective businesses,
except as would not, individually or in the aggregate, be
reasonably expected to have a Material Adverse Effect; and neither
the Company nor any of its subsidiaries has (i) received
notice from any insurer or agent of such insurer that capital
improvements or other expenditures are required or necessary to be
made in order to continue such insurance or (ii) any reason to
believe that it will not be able to renew its existing insurance
coverage as and when such coverage expires or to obtain similar
coverage at reasonable cost from similar insurers as may be
necessary to continue its business, except as would not,
individually or in the aggregate, be reasonably expected to have a
Material Adverse Effect.
13
(ii) No Unlawful Payments. Neither
the Company nor any of its subsidiaries nor, to the best knowledge
of the Company, any director, officer, agent, employee or other
person associated with or acting on behalf of the Company or any of
its subsidiaries has (i) used any corporate funds for any
unlawful contribution, gift, entertainment or other unlawful
expense relating to political activity; (ii) made any direct
or indirect unlawful payment to any foreign or domestic government
official or employee from corporate funds; (iii) violated or
is in violation of any provision of the Foreign Corrupt Practices
Act of 1977; or (iv) made any bribe, rebate, payoff, influence
payment, kickback or other unlawful payment.
(jj) Compliance with Money Laundering
Laws . The operations of the Company and its subsidiaries are
and have been conducted at all times in compliance with applicable
financial recordkeeping and reporting requirements of the Currency
and Foreign Transactions Reporting Act of 1970, as amended, the
money laundering statutes of all jurisdictions, the rules and
regulations thereunder and any related or similar rules,
regulations or guidelines, issued, administered or enforced by any
governmental agency (collectively, the “Money Laundering
Laws”) and no action, suit or proceeding by or before any
court or governmental agency, authority or body or any arbitrator
involving the Company or any of its subsidiaries with respect to
the Money Laundering Laws is pending or, to the best knowledge of
the Company, threatened.
(kk) Compliance with OFAC. None of
the Company, any of its subsidiaries or, to the knowledge of the
Company, any director, officer, agent, employee or affiliate of the
Company or any of its subsidiaries is currently subject to any U.S.
sanctions administered by the Office of Foreign Assets Control of
the U.S. Department of the Treasury (“OFAC”); and the
Company will not directly or indirectly use the proceeds of the
offering of the Securities hereunder, or lend, contribute or
otherwise make available such proceeds to any subsidiary, joint
venture partner or other person or entity, for the purpose of
financing the activities of any person currently subject to any
U.S. sanctions administered by OFAC.
(ll) No Restrictions on
Subsidiaries . Except as disclosed in or expressly contemplated
by the Time of Sale Information and the Offering Memorandum, no
subsidiary of the Company is currently prohibited, directly or
indirectly, under any agreement or other instrument to which it is
a party or is subject, from paying any dividends to the Company,
from making any other distribution on such subsidiary’s
capital stock, from repaying to the Company any loans or advances
to such subsidiary from the Company or from transferring any of
such subsidiary’s properties or assets to the Company or any
other subsidiary of the Company.
(mm) No Broker’s Fees.
Neither the Company nor any of its subsidiaries is a party to any
contract, agreement or understanding with any person (other than
this Agreement and the Amendment) that would give rise to a valid
claim against the Company or any of its subsidiaries or any Initial
Purchaser for a brokerage commission, finder’s fee or like
payment in connection with the offering and sale of the
Securities.
14
(nn) Rule 144A Eligibility .
On the Closing Date, the Securities will not be of the same class
as securities listed on a national securities exchange registered
under Section 6 of the Exchange Act or quoted in an automated
inter-dealer quotation system; and each of the Time of Sale
Information, as of the Time of Sale, and the Offering Memorandum,
as of its date, contains or will contain all the information that,
if requested by a prospective purchaser of the Securities, would be
required to be provided to such prospective purchaser pursuant to
Rule 144A(d)(4) under the Securities Act.
(oo) No Integration . Neither the
Company nor any of its “affiliates” (as defined in Rule
501(b) of Regulation D) has, directly or through any agent,
sold, offered for sale, solicited offers to buy or otherwise
negotiated in respect of, any security (as defined in the
Securities Act), that is or will be integrated with the sale of the
Securities in a manner that would require registration of the
Securities under the Securities Act.
(pp) No General Solicitation or
Directed Selling Efforts . None of the Company or any of its
affiliates or any other person acting on its or their behalf (other
than the Initial Purchasers and their affiliates, as to which no
representation is made) has (i) solicited offers for, or
offered or sold, the Securities by means of any form of general
solicitation or general advertising within the meaning of Rule
502(c) of Regulation D or in any manner involving a public
offering within the meaning of Section 4(2) of the Securities
Act or (ii) engaged in any directed selling efforts within the
meaning of Regulation S under the Securities Act
(“Regulation S”), and all such persons have
complied with the offering restrictions requirement of
Regulation S.
(qq) Securities Law Exemptions .
Assuming the accuracy of the representations and warranties of the
Initial Purchasers contained in Sections 2(b) and 5 and their
compliance with their agreements set forth therein, it is not
necessary, in connection with the issuance and sale of the
Securities to the Initial Purchasers and the offer, resale and
delivery of the Securities by the Initial Purchasers in the manner
contemplated by this Agreement, the Time of Sale Information and
the Offering Memorandum, to register the offer or sale of the
Securities under the Securities Act or to qualify the Indenture
under the Trust Indenture Act.
(rr) No Stabilization. The Company
has not taken, directly or indirectly, any action designed to or
that could reasonably be expected to cause or result in any
stabilization or manipulation of the price of the
Securities.
(ss) Business with Cuba. The
Company has complied with all provisions of Section 517.075,
Florida Statutes (Chapter 92-198, Laws of Florida) relating to
doing business with the Government of Cuba or with any person or
affiliate located in Cuba.
(tt) Margin Rules . Neither the
issuance, sale and delivery of the Securities nor the application
of the proceeds thereof by the Company as described in the Time of
Sale Information and the Offering Memorandum will violate
Regulation T, U or X of the Board of Governors of the Federal
Reserve System or any other regulation of such Board of
Governors.
15
(uu) Forward-Looking Statements. No
forward-looking statement (within the meaning of Section 27A of the
Securities Act and Section 21E of the Exchange Act) contained
in the Time of Sale Information and the Offering Memorandum has
been made or reaffirmed without a reasonable basis or has been
disclosed other than in good faith.
(vv) Statistical and Market Data.
Nothing has come to the attention of the Company that has caused
the Company to believe that the statistical and market-related data
included or incorporated by reference in the Time of Sale
Information and the Offering Memorandum is not based on or derived
from sources that are reliable and accurate in all material
respects.
(ww) Sarbanes-Oxley Act . There is
and has been no failure on the part of the Company or (to the
knowledge of the Company) any of the Company’s directors or
officers, in their capacities as such, to comply with any provision
of the Sarbanes-Oxley Act of 2002 and the rules and regulations
promulgated in connection therewith (the “Sarbanes-Oxley
Act”), including Section 402 related to loans and
Sections 302 and 906 related to certifications.
4. Further Agreements of the
Company . The Company covenants and agrees with each Initial
Purchaser that:
(a) Delivery of Copies. The Company
will deliver to the Initial Purchasers as many copies of the
Preliminary Offering Memorandum, any other Time of Sale
Information, any Issuer Written Communication and the Offering
Memorandum (including all amendments and supplements thereto) as
the Representatives may reasonably request.
(b) Offering Memorandum, Amendments or
Supplements . Before finalizing the Offering Memorandum or
making or distributing any amendment or supplement to any of the
Time of Sale Information or the Offering Memorandum or filing with
the Commission any document that will be incorporated by reference
therein, the Company will furnish to the Representatives and
counsel for the Initial Purchasers a copy of the proposed Offering
Memorandum or such amendment or supplement or document to be
incorporated by reference therein for timely review, and will not
distribute any such proposed Offering Memorandum, amendment or
supplement or file any such document with the Commission to which
the Representatives reasonably object.
(c) Additional Written
Communications. Before making, preparing, using, authorizing,
approving or referring to any Issuer Written Communication, the
Company will furnish to the Representatives and counsel for the
Initial Purchasers a copy of such written communication for timely
review and will not make, prepare, use, authorize, approve or refer
to any such written communication to which the Representatives
reasonably objects.
(d) Notice to the Representatives.
The Company will advise the Representatives promptly, and confirm
such advice in writing, (i) of the issuance by any
governmental or regulatory authority of any order preventing or
suspending the use of any of the Time of Sale Information, any
Issuer Written Communication or the Offering Memorandum or the
initiation or threatening of any proceeding for that purpose;
(ii) of the occurrence of any event at any time prior to the
completion of the initial offering of the Securities as a result of
which any of the Time of Sale Information, any Issuer Written
Communication or the Offering Memorandum as then amended or
supplemented would include any untrue statement of a material fact
or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances existing when
such Time of Sale Information, Issuer Written Communication or the
Offering Memorandum is delivered to a purchaser, not misleading;
and (iii) of the receipt by the Company of any notice with
respect to any suspension of the qualification of the Securities
for offer and sale in any jurisdiction or the initiation or
threatening of any proceeding for such purpose; and the Company
will use its commercially reasonable efforts to prevent the
issuance of any such order preventing or suspending the use of any
of the Time of Sale Information, any Issuer Written Communication
or the Offering Memorandum or suspending any such qualification of
the Securities and, if any such order is issued, will obtain as
soon as possible the withdrawal thereof.
16
(e) Ongoing Compliance of the Offering
Memorandum and Time of Sale Information . (1) If at any
time prior to the completion of the initial offering of the
Securities (which shall not be later than six months after the date
hereof) (i) any event shall occur or condition shall exist as
a result of which the Offering Memorandum as then amended or
supplemented would include any untrue statement of a material fact
or omit to state any material fact necessary in order to make the
statements therein, in the light of the circumstances existing when
the Offering Memorandum is delivered to a purchaser, not misleading
or (ii) it is necessary to amend or supplement the Offering
Memorandum to comply with law, the Company will promptly notify the
Initial Purchasers thereof and thereafter prepare and, subject to
paragraph (b) above, furnish to the Initial Purchasers such
amendments or supplements to the Offering Memorandum (or any
document to be filed with the Commission and incorporated by
reference therein) as may be necessary so that the statements in
the Offering Memorandum as so amended or supplemented (or including
such document to be incorporated by reference therein) will not, in
the light of the circumstances existing when the Offering
Memorandum is delivered to a purchaser, be misleading and
(2) if at any time prior to the Closing Date (i) any
event shall occur or condition shall exist as a result of which any
of the Time of Sale Information as then amended or supplemented
would include any untrue statement of a material fact or omit to
state any material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were
made, not misleading or (ii) it is necessary to amend or
supplement any of the Time of Sale Information to comply with law,
the Company will promptly notify the Initial Purchasers thereof and
thereafter prepare and, subject to paragraph (b) above,
furnish to the Initial Purchasers such amendments or supplements to
any of the Time of Sale Information (or any document to be filed
with the Commission and incorporated by reference therein) as may
be necessary so that the statements in any of the Time of Sale
Information as so amended or supplemented will not, in light of the
circumstances under which they were made, be misleading.
(f) Blue Sky Compliance. The
Company will qualify the Securities for offer and sale under the
securities or Blue Sky laws of such jurisdictions as the
Representatives shall reasonably request and will continue such
qualifications in effect so long as required for the offering and
resale of the Securities; provided that the Company shall
not be required to (i) qualify as a foreign corporation or
other entity or as a dealer in securities in any such jurisdiction
where it would not otherwise be required to so qualify,
(ii) file any general consent to service of process in any
such jurisdiction or (iii) subject itself to taxation in any
such jurisdiction if it is not otherwise so subject.
17
(g) Clear Market. For a period of
90 days after the date of the offering of the Securities, the
Company will not (i) offer, pledge, announce the intention to
sell, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any
option, right or warrant to purchase or otherwise transfer or
dispose of, directly or indirectly, or file with the Securities and
Exchange Commission any registration statement relating to, any
shares of Common Stock or any securities convertible into or
exercisable or exchangeable for Common Stock or (ii) enter
into any swap or other agreement that transfers, in whole or in
part, any of the economic consequences of ownership of the Common
Stock or any such other securities, whether any such transaction
described in clause (i) or (ii) above is to be settled by
delivery of Common Stock or such other securities, in cash or
otherwise, without the prior written consent of J.P. Morgan
Securities Inc., in each case of clause (i) or (ii), other
than the Securities to be sold hereunder and any shares of Common
Stock of the Company issued under employee stock option
plans.
(h) Use of Proceeds. The Company
will apply the net proceeds from the sale of the Securities as
described in the Time of Sale Information and the Offering
Memorandum under the heading “Use of
Proceeds”.
(i) No Stabilization. The Company
will not take, directly or indirectly, any action designed to or
that could reasonably be expected to cause or result in any
stabilization or manipulation of the price of the Securities and
will not take any action prohibited by Regulation M under the
Exchange Act in connection with the distribution of the Securities
contemplated hereby.
(j) Underlying Securities . For so
long as the Company is subject to such corresponding requirement
under the terms of the Indenture, the Company will reserve and keep
available at all times, free of pre-emptive rights, shares of
Common Stock for the purpose of enabling the Company to satisfy all
obligations to issue the Underlying Securities upon conversion of
the Securities. The Company will use its best efforts to cause the
Underlying Securities to be listed on the New York Stock Exchange
(the “Exchange”).
(k) Supplying Information . For so
long as the Company is subject to such corresponding requirement
under the terms of the Indenture, while the Securities remain
outstanding and are “restricted securities” within the
meaning of Rule 144(a)
|